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Abstract
Background:  Since esophageal variceal bleeding is associated with a high mortality rate,
prevention of bleeding might be expected to result in improved survival. The first trials to evaluate
prophylactic sclerotherapy found a marked beneficial effect of prophylactic treatment. These
results, however, were not generally accepted because of methodological aspects and because the
reported incidence of bleeding in control subjects was considered unusually high. The objective of
this study was to compare endoscopic sclerotherapy (ES) with nonactive treatment for the primary
prophylaxis of esophageal variceal bleeding in patients with cirrhosis.
Methods: 166 patients with esophageal varices grade II, III of IV according to Paquet's classification,
with evidence of active or progressive liver disease and without prior variceal bleeding, were
randomized to groups receiving ES (n = 84) or no specific treatment (n = 82). Primary end-points
were incidence of bleeding and mortality; secondary end-points were complications and costs.
Results: During a mean follow-up of 32 months variceal bleeding occurred in 25% of the patients
of the ES group and in 28% of the control group. The incidence of variceal bleeding for the ES and
control group was 16% and 16% at 1 year and 33% and 29% at 3 years, respectively. The 1-year
survival rate was 87% for the ES group and 84% for the control group; the 3-year survival rate was
62% for each group. In the ES group one death occurred as a direct consequence of variceal
bleeding compared to 9 in the other group (p = 0.01, log-rank test). Complications were
comparable for the two groups. Health care costs for patients assigned to ES were estimated to be
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higher. Meta-analysis of a large number of trials showed that the effect of prophylactic
sclerotherapy is significantly related to the baseline bleeding risk.
Conclusion: In the present trial, prophylactic sclerotherapy did not reduce the incidence of
bleeding from varices in patients with liver cirrhosis and a low to moderate bleeding risk. Although
sclerotherapy lowered mortality attributable to variceal bleeding, overall survival was not affected.
The effect of prophylactic sclerotherapy seems dependent on the underlying bleeding risk. A
beneficial effect can only be expected for patients with a high risk for bleeding.
Background
About one-third of patients with liver cirrhosis and varices
are likely to undergo hemorrhage during their lifetime [1–
5]. The average mortality due to the first variceal bleeding
has been estimated to be about 30–50% [1,6,7]. Variceal
bleeding therefore represents a frequent cause of death
and one might expect survival to improve if bleeding
could be prevented.
The potential of primary prevention of variceal bleeding
to improve prognosis is dependent on the severity of the
underlying disease. There is a close relationship between
(risk of) bleeding and degree of liver failure. Often bleed-
ing precipitates or exacerbates liver failure, while deterio-
rating liver function frequently precedes variceal bleeding.
Obviously, prevention of bleeding in end-stage disease is
unlikely to affect prognosis. For patients with a relatively
preserved liver function, however, prevention of bleeding
might improve prognosis, by reducing mortality due to
exsanguination as well as from the complications fre-
quently encountered after variceal bleeding, including
hepatorenal syndrome, infections and multi-organ
failure.
The first type of primary prophylaxis evaluated was the
portacaval shunt [3–5]. Although shunt surgery reduced
the frequency of bleeding, the rate of both mortality and
encephalopathy was increased. Data on other prophylac-
tic surgical procedures are limited and do not allow con-
clusions [8].
The first reports on the use of prophylactic sclerotherapy
suggested that this procedure not only significantly
reduced the incidence of variceal bleeding [9–12] but also
lowered overall mortality [10,12]. However, the results of
these trials were disputed, mainly because the reported
bleeding risk for control patients in some studies was con-
sidered exceptionally high and treatment of acute variceal
bleeding episodes was not the same for the two treatment
groups [1,13].
The aim of the present multicentre study was to evaluate
the effect of endoscopic sclerotherapy for the primary pre-
vention of variceal bleeding in an adequate number of
patients with cirrhosis and esophageal varices, with uni-
form treatment of variceal bleeding in both groups.
Methods
Patient selection
Eligible patients were adults with endoscopically docu-
mented grade II, III or IV esophageal varices [14], absence
of prior bleeding from varices, evidence of active and/or
progressive liver disease (e.g. as indicated by repeatedly
elevated serum transaminases or increasing serum
bilirubin levels or development of ascites within the past
year) or documented increase in the size of esophageal
varices; all patients gave informed consent. Patients were
excluded for the following reasons: use of β-blockers and
nitrates, malignancy, hemophilia, age older than 70–75
years, no opportunity for follow-up visits.
Centers, study design, randomization and informed 
consent
This was a multicentre randomized controlled trial that
started on 1 May 1986. Patients were included until May
1993 and followed until November 1993. Participating
centers (number of patients in parentheses) were the Uni-
versity Hospital Rotterdam (coordinating center)(81); the
University Hospital Utrecht (25); the Zuiderziekenhuis,
Rotterdam (17); the Academic Medical Center, Amster-
dam (15); the Ziekenhuis Leyenburg (12) and Westeinde
Hospital (10), The Hague; and the Reinier de Graaf
Gasthuis, Delft (6).
Randomization was performed according to Zelen's pre-
randomization design [15]. After assessment of eligibility,
patients were randomized and provided with oral and
written information; they were then asked to participate
and give informed consent. This procedure was expected
to facilitate patient entry, being considered defensible and
appropriate taking into account the marked difference
between the two treatment options [16]. The medical eth-
ical committee of one center did not approve of the pre-
randomization method; in this center the conventional
procedure was followed.
Treatment was assigned centrally, by telephone contact or
by visiting the trial office, using opaque, serially num-
bered sealed envelopes. Patients were stratified for centerBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/22
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and severity of liver disease according to the Child-Pugh
classification [17]. Follow-up started at the time of rand-
omization. Patients gave written informed consent. The
medical ethical committees of the participating centers
approved the trial.
Endoscopic sclerotherapy
Experienced endoscopists performed all procedures using
fiber or video-endoscopes. Patients received intravenous
sedation consisting of 0.075 – 0.2 mg midazolam/kg.
Varices were injected at multiple sites with 0.5–3 ml
ethoxysclerol (polidocanol) 1% or 2% (Kreussler, Ger-
many), proceeding upwards from the gastroesophageal
junction. The maximum injection volume was 35 ml/ses-
sion. Patients were hospitalized for the first sclerotherapy
session. Successive treatments were planned on an outpa-
tient basis at 3-week intervals until variceal obliteration
was achieved. The aim of sclerotherapy was complete
variceal eradication. Subsequently control examinations
were performed at 6-month intervals. Recurrent varices
were treated. When eradication was established on two
subsequent visits further control examinations were
scheduled at yearly intervals.
Entry and follow-up procedures
Before randomization, all patients underwent upper gas-
trointestinal endoscopy. Esophageal varices were classi-
fied according to Oberhammer and Paquet [14]. Meetings
of participants were organized to review and standardize
diagnostic aspects. The Child-Pugh classification system
[17] was used as a measure of functional hepatic reserve.
General care of the patients in both groups was identical
and involved clinical and biochemical assessment at 3-
month intervals.
Definition of key events; management of rebleeding and 
complications
We used international consensus definitions of variceal
bleeding and variceal rebleeding. Variceal bleeding was
diagnosed when endoscopy, performed within 24 hours
after occurrence of hematemesis or melena, showed active
variceal bleeding, signs of recent bleeding ("white nipple
sign" or adherent clot) or showed varices without another
potential source of bleeding in the presence of blood in
the stomach. [18]. For both groups, the standard therapy
for variceal bleeding was resuscitation followed by endo-
scopic sclerotherapy according to the methods described
above, but at intervals of one week until variceal oblitera-
tion was achieved. Subsequently, follow-up examinations
were performed after 3 months, and then at 6, 9 and
finally 12-month intervals. Balloon tamponade was per-
formed when variceal bleeding was not controlled by ES
for a period of up to 24 hours and was followed by
renewed ES. Therapy for patients with persistent or recur-
rent variceal bleeding was not defined and decisions were
left to the discretion of the individual hospital depart-
ments. Variceal obliteration was defined as variceal
thrombosis and absence of variceal blood flow as assessed
by needle puncture. Variceal eradication was defined as
visual absence of variceal columns. Procedure-related
mortality was defined as death within 30 days of ES.
Esophageal mucosal ulcers after ES were not regarded as a
complication unless they caused symptoms, including
bleeding and pain.
Analysis of costs
An estimation of the direct medical costs was made by
comparing the time spent in the intensive care unit and
the ordinary ward, the number of visits to the outpatient
department and the number of upper gastrointestinal
endoscopies, including sclerotherapy procedures. Only
patients admitted to the University Hospital Rotterdam
were included. Indirect costs, e.g. economic loss due to
inability to work, were not taken into consideration.
Statistics
A sample size calculation was performed assuming a 30%
and 10% incidence of bleeding 3 years after entry for the
control and ES groups, respectively. To detect this differ-
ence with a significance level (alpha) of 0.05 and a power
of 90%, and using a two-tailed test, we calculated that we
needed to recruit 79 patients for each treatment group.
Analyses were performed on an intent-to-treat basis. The
primary end-points of this study were variceal bleeding
and mortality. Secondary end-points were complications
and health-care costs.
Bleeding and mortality were analyzed using the Kaplan-
Meier method. Differences between groups were com-
pared by means of the log-rank test. The χ2 test was used
to analyze differences between groups for qualitative data.
Paired and unpaired t-tests, or their non-parametric
equivalents where appropriate, were used for quantitative
data. For analyzing the relationship between baseline
bleeding risk and the effect of prophylactic sclerotherapy
on the risk of a first variceal bleeding, as reported in the
literature and including data of the present trial, the
method proposed by Arends et al [19]was used. A two-
tailed p-value = 0.05 was considered significant.
Results
Of the 166 patients enrolled in the study 84 were rand-
omized to undergo ES and 82 to the control group (Figure
1). Patient characteristics of the two groups were compa-
rable (table 1). Mean follow-up was 32 ± SD 25 (range 0.1
– 88.5) months; for the ES group 30 ± 23 months and for
controls 34 ± 27 months. Follow-up was incomplete for
11 (ES group 7) patients due to removal, emigration or
other reasons. For these cases data were censored at the
time of the last visit. In all cases, however, efforts wereBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/22
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undertaken to determine whether the patients were alive
at the time of analysis and this information, including
causes of death, was used for analysis.
Procedures
For sixteen patients assigned to undergo ES, treatment was
not instituted because of refusal (n = 13), concomitant
medical problems (n = 2) or miscommunication resulting
in failure to initiate ES (n = 1). ES was offered to one con-
trol patient who repeatedly expressed the explicit wish to
be treated because of fear of bleeding. No patient refused
to participate in the trial with respect to the prospective
recording of follow-up data. During follow-up 9 patients
of the control group and 4 of the ES group received a liver
transplant. For these cases data were censored at the time
of transplantation.
Sclerotherapy resulted in variceal eradication in 47/68
(69%) of patients who actually received prophylactic scle-
rotherapy. The mean volume of sclerosant to achieve erad-
ication was 76 ml (SD 45, range 6–209) and the mean
number of sclerotherapy sessions 5.7(SD 2.5, range 2–
14). After eradication varices recurred in 6/47 (13%)
patients.
Bleeding
(Table 2) Both the number of patients and the number of
episodes of variceal bleeding in the two groups were com-
parable. The same applied for bleeding due to non-
variceal causes. The incidence of bleeding from varices
(Figure 2) for the ES and control groups was 16% and
16% at 1 year, 29% and 29% at 3 years and 33% and 35%
at 4 years, respectively (NS). Variceal bleeding occurred in
7 of 16 (43%) patients of the ES group who did not
receive therapy. For 10/14 patients of the ES group
variceal bleeding occurred early (mean 3.5 months, range
1 day – 9 months), before variceal eradication had been
achieved. Two of these patients had a variceal bleeding
after randomization but before ES was started. In 4
patients who had ES which resulted in variceal eradica-
tion, variceal bleeding occurred after a mean period of 28
months and 5.5 (range 4–9) ES sessions.
Trial profile Figure 1
Trial profile.
Table 1: Patient characteristics at entry
Characteristic Sclerotherapy 
n = 84
Controls n = 82
Age 56(23–76) 55(20–72)
Sex (M/F) (n) 46/38 49/33
Diagnosis
Alcoholic liver disease 41 40
Hepatitis B/C 24 21
PBC/PSC 11 8
Other 24 31
Child-Pugh class A/B/C (n) 44/32/8 47/25/10
Child-Pugh score 6(5–12) 6(5–13)
Esophageal varices
grade II 47 42
grade III 38 40
grade IV 15 18
Ascites 44 37
Laboratory
Bilirubin (µmol/l) 27(7–429) 27(7–217)
Albumin (g/l) 36(18–48) 35(23–47)
AT-III (IE/l) 0.7(0.22–1.45) 0.7(0.24–1.32)
ASAT (U/l) 44.5(12–264) 49(12–373)
Results are expressed as percentages and medians with ranges, unless 
otherwise indicated. Normal ranges: serum bilirubin <18 µmol/l; 
albumin > 37 g/l; AT-III 0.85 – 1.50 IE/l; ASAT < 35 U/l
eligible patients n=166
(pre)-randomization
control group
n = 82
sclerotherapy
 n = 84
did not receive
sclerotherapy
n=16
analyzed n = 84
control group
n = 81
sclerotherapy
n = 68
analyzed n=82
sclerotherapy
n = 1
Table 2: Variceal bleeding
Sclerotherapy 
n = 84
Controls n = 82
Patients (n)
Variceal bleeding 21 (25%) 23 (28%)
Non-variceal bleeding 7(8%) 7(8.5%)
Episodes
Variceal bleeding 32 39
All upper GI-bleeding 48 49
Child-Pugh class
A 11/44 11/47
B 8/32 8/25
C2 / 84 / 1 0BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/22
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Variceal bleeding occurred more frequent in patients with
Child class B and C (Table 2), but differences were not sta-
tistically significant (p = 0.9, log-rank test). For the ES
group, the 3-year risk of variceal bleeding for Child A
patients was 25%, for Child B patients 32% and for Child
C patients 34% (p = 0.6). For control patients the respec-
tive percentages were 28%, 31% and 22% (p = 0.1).
The incidence of upper gastrointestinal hemorrhage due
to all causes was 22% for the ES group and 25% for the
control group after 1 year and 35 and 36 % after 3 years.
Per protocol analysis of those patients who underwent the
allocated treatment showed that the incidence of variceal
hemorrhage for the ES and control group was 17% and
14% after 1 year and 19% and 29% after 3 years, respec-
tively (NS). The 1 and 2 year incidence of upper gastroin-
testinal hemorrhage due to all causes was 21% and 29%
for the ES group and 15% and 36% for the control group,
respectively (NS).
Mortality
Twenty-nine (35%) patients of the ES group died and 33
(40%) of the control group (Table 3). In the ES group only
1 death occurred as a direct consequence of variceal bleed-
ing compared to 9 in the other group (p = 0.01, log-rank
test). The frequency of other causes of death was compa-
rable. The 1-year survival rate was 87% for the ES group
and 84% for the control group; the 3-year survival rate was
62% for each group (figure 3). Univariate analysis showed
that 3-year survival for Child-Pugh class A, B and C
patients was 77%, 45% and 31% (p = 0.05). For the ES
group, survival at 3 years for Child-Pugh class A patients
was 86%, for class B patients 38% and for class C patients
29% (p = 0.0001). For the control group 3-year survival
for class A, B and C was 70%, 55% and 31% (p = 0.0001).
No relationship was found between mortality and the size
of esophageal varices, etiology of liver disease or
participating center.
Kaplan-Meier plot showing the percentage of patients free of  variceal bleeding (S: sclerotherapy group; C: control group Figure 2
Kaplan-Meier plot showing the percentage of patients free of 
variceal bleeding (S: sclerotherapy group; C: control group.
Table 3: Causes of death
Sclerotherapy 
n = 84
Controls n = 82
total n = 29 n = 33
Variceal bleeding 1 9
Liver failure 9 13
Hepatocellular carcinoma 5 3
Other causes
Malignancy 2
Infection 4 3
Stroke 1 3
Bleeding from duodenal 
ulcer
1
Postoperative multi-
organ failure
1
Hypothermia 1
Esophageal perforation1 1
Unknown 4 1
1 complication of sclerotherapy Values are number of patients
year
%
S
C
Kaplan-Meier plot showing the percentage of surviving  patients (S: sclerotherapy group; C: control group) Figure 3
Kaplan-Meier plot showing the percentage of surviving 
patients (S: sclerotherapy group; C: control group). Overall 
survival (black lines) was comparable. Mortality due to 
variceal bleeding (dotted lines) in the sclerotherapy group 
was significantly lower than in the control group (p = 0.01)
%
year
S
C
S
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Per protocol analysis of those patients who underwent the
allocated treatment showed that survival for the ES (n =
68) and control (n = 82) group was 85% and 84% after 1
year and 61% and 62% after 3 years, respectively (NS).
Complications
Table 4 shows the number of patients who had complica-
tions believed to be related to sclerotherapy. Complica-
tions for the control group occurred after sclerotherapy
was performed for treating acute variceal bleeding or to
prevent rebleeding. One fatal complication occurred in a
patient of the ES group due to esophageal perforation
after two treatment sessions. Two patients developed
symptomatic submucosal esophageal hematomas, and in
one case this complication was observed on two occa-
sions. In all cases spontaneous and complete resolution
ensued. Two to four endoscopic dilatations were required
in 3 cases of esophageal stenosis following sclerotherapy;
in all cases the symptoms were alleviated. We found no
evidence that the frequency of complications differed
between centers. 8 /91 (9%) Child-Pugh class A patients
suffered a complication compared to 8/57 (14%) class B
patients and 1/18 (6%) class C patients (NS). Thus, no
clear relationship was found between the risk of compli-
cations and the severity of liver disease.
Costs
In the University Hospital Rotterdam, 299 upper gastroin-
testinal procedures were carried out in 41 patients
assigned to receive ES, compared to 89 procedures for the
control group (n = 40) (p = .0001). The mean number of
days in hospital was 55 for the ES and 35 for the control
patients (NS). The total number of days in hospital was
2277 for the ES group and 1400 for the control group (p
= 0.05). The time spent in intensive care (ES group 58,
controls 48) was comparable but ES patients spent signif-
icantly more time in other wards (2219 vs. 1352 days).
The numbers of visits to the outpatient department (ES
group: mean 13.4; total 549; control group: mean 12.8;
total 512) were comparable. Altogether, these data indi-
cate that ES was the more expensive strategy, suggesting
that the initially higher costs of prophylaxis due to
hospital admissions and endoscopic procedures were not
compensated by potentially decreased medical consump-
tion over time.
Discussion
In this randomized trial primary prevention of variceal
bleeding using endoscopic sclerotherapy did not reduce
the bleeding risk for patients with liver cirrhosis and
esophageal varices. We found that prophylactic sclero-
therapy lowered the risk of fatal variceal bleeding without
affecting overall survival. Finally, complications and costs
were more marked among patients receiving endoscopic
prophylaxis.
Several factors could possibly explain why sclerotherapy
was not found to reduce the risk of variceal bleeding in the
current trial. We may have failed to detect a real treatment
effect, a type II statistical error. Although the sample size
of this study seemed adequate, a type II error remains a
realistic possibility, in particular because nearly 20% (16/
84) of patients did not undergo the assigned sclerotherapy
treatment. Since the bleeding risk for this particular sub-
group was high, this may have diluted the beneficial
effects of endoscopic prophylaxis. Although per protocol
analysis showed a trend in favor of this possibility, it was
not significant. Another factor that could have obscured
benefits of ES is an unexpected low bleeding rate for the
control group. However, we found that the 3-year bleed-
ing risk for control patients was very similar to the
predicted 30%, and consequently that this factor does not
seem of importance. Although this was a randomized
trial, one can never guarantee similarity between groups
as far as prognostic variables are concerned. Moreover,
differences between groups in baseline bleeding risk could
be a source of bias. The distribution of variables of prog-
nostic significance in the two groups, particularly Child-
Pugh scores, age and variceal size, however, make it
unlikely that such a bias was important. Sclerotherapy
could increase the initial risk of (variceal) bleeding but
have a protective effect over time, eventually translating
into an overall treatment benefit. We found some evi-
dence to support this possibility since the majority of
variceal bleeding episodes were observed before achieving
variceal eradication, and bleeding after eradication was a
rare event. It has been noted previously that the bleeding
risk for patients recruited for trials of prophylactic therapy
Table 4: Complications of sclerotherapy
Sclerotherapy 
n = 84
Controls n = 82
Esophagus
Bleeding from ulceration 2 3
Submucosal esophageal 
hematoma
2
Stenosis 2 2
Perforation 1
Food impaction 1
Dysphagia 1
Infections
Bacteremia 1
Bacterial peritonitis 1
Pneumonia 1
Total 11 6
Values are numbers of patients Complications in the control group 
occurred after sclerotherapy was performed either to arrest active 
variceal bleeding or to prevent rebleedingBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/22
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seems highest during the first months of follow-up and
decreases to about 1/3 after one year [1,3]. This may sug-
gest that, in retrospect, our sclerotherapy protocol was not
optimal and a more intensive regimen, resulting in more
rapid eradication of varices [20], could have been more
effective.
In this trial ES significantly reduced the mortality rate for
variceal bleeding, a finding also reported by other groups
[10,20–24]. In only a few studies, however, was this asso-
ciated with a corresponding improvement in overall sur-
vival [10,20,21,24]. In these studies variceal bleeding
occurred in at least 50% of control patients and was the
main cause of death, accounting for 65–80% of mortality.
This suggests that the magnitude of the effect of prophy-
lactic sclerotherapy on the risk for variceal bleeding, but
also on mortality, is dependent on the baseline bleeding
risk. This hypothesis was supported by D'Amico, who
found a clear relationship between the effect of sclerother-
apy on the incidence of bleeding and the base line bleed-
ing risk as reported in a large number of randomized
controlled trials [25]. We also analyzed the relationship
between baseline risk and treatment effect using the
method proposed by Arends et al. [19]. We found, in
agreement with D'Amico's results, that a significant (p <
0.001) relationship exists between the baseline bleeding
risk and the effect of treatment when analyzing the results
of trials of prophylactic sclerotherapy (Figure 4 and 5),
which cannot be attributed to 'regression to the mean'.
Thus, endoscopic sclerotherapy is likely to reduce bleed-
ing risk, and probably also mortality, only for patients
with a particularly high risk of bleeding. Identification of
such patients is possible using the NIEC, or comparable,
indices [26,27]. For patients with a low bleeding risk, the
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding Figure 4
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding. The trials are arranged 
according to the baseline bleeding-risk, expressed as the odds after logarithmic transformation for the control groups.
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effect of sclerotherapy will be marginal or absent;
sclerotherapy might even have a deleterious effect. The
numerous trials on prophylactic sclerotherapy have been
subjected to meta-analysis [28–31]. All studies have pro-
duced a statistically significant pooled estimate of treat-
ment effect on bleeding risk and mortality in favor of
sclerotherapy. Like the results of the individual studies,
the conclusions based upon these analyses have been
diverse, varying from an undetermined effect of
sclerotherapy [29,30] to sclerotherapy being effective, par-
ticularly for high-risk patients [28,31]. One meta-analysis
[31] yielded a marked difference in the outcome of trials
according to the type of sclerosant used, the results clearly
favoring polidocanol. The general recommendation
emerging from international consensus conferences
[18,32,33] has been that sclerotherapy should not be used
for primary prophylaxis of variceal bleeding, mainly
because of the statistically significant heterogeneity of the
treatment effects as observed in studies, and the
availability of a non-invasive and cheap alternative (non
selective β-blocker treatment).
When the trial was designed the possibility existed that, as
a result of the pre-randomization method, not all patients
would accept the assigned treatment. In practice, refusal
proved to be a more frequent problem than expected,
which complicated the interpretation of results. However,
this problem is not unique to the pre-randomization
method and similar difficulties can occur with conven-
tional randomization [3,5,34–36]. Otherwise, no prob-
lems were encountered and our general experience was
that the method worked well. Unfortunately, our study
design did not allow us to assess whether pre-randomiza-
tion indeed resulted in increased patient recruitment. Pre-
randomization has the potential advantage that, at least in
theory, all eligible patients will be selected while the con-
ventional method implies that only a selection of eligible
patients will be entered. Consequently, the results of trials
using this allocation method may have wider
applicability.
The observed rate of complications of sclerotherapy in
this study is in agreement with previously reported data.
In some studies, however, complications were much more
frequent [37,38]. An explanation for these divergent
results remains speculative. Variations in technique [31],
technical skill and experience with endoscopic
sclerotherapy could at least partially account for some of
the reported differences.
Our estimation of costs was based on a proportion of
patients and the results obviously are preliminary in
nature. Nevertheless, our data suggest that prophylactic
treatment was the more expensive option. Taking into
account the other findings, the cost/benefit ratio of
prophylactic sclerotherapy as applied in this study seems
unfavorable.
Conclusions
The present results does not support the use of sclerother-
apy for primary prevention of variceal bleeding when
patients are selected according to the criteria we used.
Nevertheless, according to cumulative data from a large
number of trials, it can be concluded that endoscopic scle-
rotherapy can result in a significant decrease in the bleed-
ing risk and, probably, also in bleeding-associated
mortality, but only in selected cases with a high bleeding
risk. On the basis of lower rates of rebleeding, mortality,
complications and the need for fewer endoscopic treat-
ments, variceal band ligation has been shown to be supe-
rior to sclerotherapy for secondary prophylaxis of variceal
bleeding [39]. Several trials have now evaluated band liga-
tion for primary prophylaxis of variceal bleeding. In most,
but not all [40], studies band ligation significantly
reduced the bleeding risk when compared to control
patients [40–42] or administration of propranolol [43],
and in one study ligation was also found to improve
survival [42]. Additional studies comparing band ligation
and non-selective β-blockers are needed before the role of
ligation for primary prevention of variceal bleeding can be
defined more precisely. For the time being, β-blockers
remain the principal option for primary prophylaxis of
variceal bleeding. For patients with contraindications or
intolerance for β-blockers and for those who are not com-
pliant or do not respond to treatment, variceal band
Meta-analysis (19) of the effect of prophylactic sclerotherapy  on the incidence of variceal bleeding Figure 5
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ligation rather than sclerotherapy may be considered for
primary prophylaxis [44].
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